Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBX-3400
- Development stage
- Phase 2
- Lead developer
- Taiga Biotechnologies
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TBX-3400 is an investigational, cell-based immunotherapy developed by Taiga Biotechnologies. It consists of autologous peripheral blood mononuclear cells (PBMCs) from the patient, which are treated ex vivo with a recombinant TAT-MYC fusion protein known as TBX-4000. This process transiently alters intracellular MYC levels in immune cells, enabling them to overcome tumor-induced suppressive signals and enhance anti-tumor activity upon reinfusion into the patient. The therapy aims to boost immune response against cancer and potentially certain viral infections by temporarily liberating immune cells from inhibitory mechanisms. Primary indications under investigation include relapsed or refractory metastatic melanoma and other solid tumors resistant to standard therapies[1][2][3][8].
- Other names
- autologous human peripheral blood mononuclear cells incubated ex vivo with protein TBX-4000 (Tat-MYC)
02
Targets
MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on TBX-3400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBX-3400.